Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.20.2
Consolidated Statements of Operations - USD ($)
12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Expenses    
Research and development $ 3,630,024 $ 3,662,056
General and administrative 4,514,520 4,736,440
Merger costs 1,053,697  
Operating expenses 9,198,241 8,398,496
Other (income) loss    
Change in fair value of derivative liabilities   (433,503)
Derivative liability issue costs   126,186
Foreign exchange loss 2,923 17,746
Interest income (75,248) (60,704)
Other loss (income) (72,325) (350,275)
Net loss for the year 9,125,916 8,048,221
Computation of basic loss per share    
Net loss for the year 9,125,916 8,048,221
Series B Preferred stock dividend 8,616 80,431
Net loss for the year attributable to common stockholders $ 9,134,532 $ 8,128,652
Basic and fully diluted loss per share $ 0.87 $ 3.16
Basic and fully diluted weighted average number of shares 10,444,045 2,574,692